The disclosure relates to compounds of formula I wherein the various unspecified groups are as described in the specification. The disclosure also relates to the process to synthesise it and the use of these compounds to treat depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson&rsquo；s disease, neurodegenerative disorders such as Alzheimer&rsquo；s disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. Example compounds include: (RS)-5-Chloro-N-(5-(morpholin-2-yl)pyridin-2-yl)pyridin-2-amine (RS)-5-Bromo-N-(5-(morpholin-2-yl)pyridin-2-yl)pyridin-2-amine (RS)-5-Cyclopropyl-N-(5-(morpholin-2-yl)pyridin-2-yl)pyrimidin-2-amine [(RS)-1-(5-Bromo-pyridin-2-yl)-2,2,2-trifluoro-ethyl]-((RS)-4-pyrrolidin-3-yl-phenyI)-amine (5-Bromo-pyridin-2-ylmethyl)-((S)-4-morpholin-2-yl-phenyl)-amine (6-Methoxy-pyridin-2-ylmethyl)-((S)-4-morpholin-2-yl-phenyl)-amine (4-Methyl-benzyl)-((S)-4-morpholin-2-yl-phenyl)-amine 4-[((S)-4-Morpholin-2-y l-phenylamino)-methyl]-benzonitrile ((S)-4-Morpholin-2-yl-phenyl)-(4-trifluoromethyl-benzyl)-amine ((S)-4-Morpholin-2-yl-phenyl)-(4-trifluoromethoxy-benzyl)-amine.
